Could a common diabetes drug keep your heart in rhythm?
NCT ID NCT07187570
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether dapagliflozin, a drug typically used for diabetes, can prevent atrial fibrillation from coming back after a procedure called cardioversion (an electric shock to restore normal heart rhythm). About 1600 adults with AF will take either dapagliflozin or no extra drug for up to 56 days. Researchers will track heart rhythm using a handheld device to see if the drug reduces recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin (a diabetes drug that lowers blood sugar and may help heart rhythm)
What this could lead to
If it works, this could offer a new, short-term treatment to prevent atrial fibrillation from coming back after cardioversion.
What could go wrong
This is a phase 3 trial, but it's still early to know if dapagliflozin truly helps AF. The drug may not reduce recurrence, and side effects like dehydration or kidney issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Akademiska sjukhuset
NOT_YET_RECRUITINGUppsala, 75389, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Danderyds Hospital
NOT_YET_RECRUITINGStockholm, 18527, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Karolinska University Hospital
RECRUITINGStockholm, 14186, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Linköping university hosptial
NOT_YET_RECRUITINGLinköping, 58225, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Norrlands universitetssjukhus
NOT_YET_RECRUITINGUmeå, 90185, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Södersjukhuset
NOT_YET_RECRUITINGStockholm, 11861, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Örebro University hospital
RECRUITINGÖrebro, 70382, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact